@jonchou05 delivers a tour de force presentation @AACR on resistance mechanisms to NECTIN4 therapy (enfortumab and CAR-T) in bladder cancer. @UCSFCancer #AACR26 The takeaways:

10/ APEX linked luminal programs to favorable outcomes and EMT signatures to poor outcomes. In enfortumab vedotin–treated bladder cancer, 58% of patients with high APEX-predicted NECTIN4 responded, compared to 0% with low NECTIN4. Even after adjusting for tumor fraction, copy number, and clinical covariates, APEX-derived NECTIN4 remained independently associated with improved survival. Our preliminary data suggests that plasma-inferred NECTIN4 may outperform tissue NECTIN4 IHC in this task.

Thanks to @UCSFCancer for covering our study which showed that a PPARg agonist rosiglitazone (an old diabetes drug) can modulate NECTIN4 & enhance activity of a new CAR T in #bladdercancer @CChuMD @koshkin85 @DrTFriedlander @SimaPorten @UCSFUrology ucsf.edu/news/2025/09/430701…

Research funded in part by BCAN with @jonchou05 in @NatureComms : Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Click here to read the article: nature.com/articles/s41467-0…

In @naturecomms: Bladder cancer variants share aggressive features including a CA125 cell state and targetable TM4SF1 expression. Click here to read the article: nature.com/articles/s41467-0…

UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡@bcan_chisolm @UCSFCancer @UCSFUrology @SimaPorten @jonchou05 @koshkin85 @SamWashUro

📢Check out this Article NOW ONLINE! @NatureCancer '#Transcription and #DNAreplication collisions lead to large tandem duplications and expose targetable #therapeutic vulnerabilities in #cancer' ✏️By Jonathan Chou, Lixing Yang and colleagues 📎nature.com/articles/s43018-0…

🔥 Hot off the press: Lixing Yang, PhD, and collaborators at @UCSF have published a ground breaking work in @NatureCancer, demonstrating how unrepaired collision of DNA replication and transcription can drive aggressive cancers. @UChicagoCCB @jonchou05 ow.ly/VkTT50U9bYt

📕 New publication alert: Lixing Yang, PhD and his collaborators at @UCSF published an exciting work demonstrating new approaches to correct the errors generated by the collision of DNA replication and transcription. @jonchou05 @NatureCancer @UChicagoCCB ow.ly/QEtK50UahjS

In prostate cancer, sensitivity to poly ADP-ribose polymerase inhibitors is dependent on the specific type and zygosity of the CDK12 mutation, reports Dr. Jonathan Chou's team at @UCSF. bit.ly/3zBmdzq

Thanks @jonchou05 for visiting @fredhutch fantastic talk & dinner! @HsiehLab @li_haolong @DrOmarMian @JLWrightMD @koshkin85 @GavinHa @DrTFriedlander @BladderCancerUS @Uromigos @JoshMeeks @TiansterZhang @jklee_lab @FaltasLab Great opportunities for collaboration & translation!

Awesome #BCANTT24 this year. Great representation from #UCSF!

Histologic variants in bladder cancer harbor aggressive molecular features including TM4SF1 expression and a CA125 cell state biorxiv.org/cgi/content/shor… #biorxiv_cancer

We are happy to share our new study published today @JCO_ASCO (👉 ascopubs.org/doi/10.1200/JCO…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered the role of NECTIN4 amplifications in enhancing the efficacy of Enfortumab Vedotin (EV), a cutting-edge treatment for metastatic urothelial cancer (mUC). With NECTIN4 amplifications positioned as a potential genomic marker to predict responses to EV in mUC patients, let's explore how these findings could translated to other cancer entities as well! Summary 👉 in posts below! Link to paper: ascopubs.org/doi/10.1200/JCO… @AmerUrological @Uroweb @ASCO @PathSoc #Uropathology #urothelial #cancer #MedicalInnovation @NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper #pathtwitter @HolzelMichael @IEO_HolzelLab @brookmans76 @PGrivasMDPhD @DrYukselUrun @shilpaonc @drenriquegrande @amerseburger @JoshMeeks @roghmann @IvanyiPhilipp @GNiegisch @ViktorGruenwald @KuppeChristoph @AlbertoNakauma @OncoBellmunt @tompowles1 @montypal @DrChoueiri @neerajaiims @PTarantinoMD @sonpavde @DrRosenbergMSK @Dr_Aggen @koshkin85 @jonchou05 @EKFStiftung @dfg @UniFAU

Thanks @scserendipity1 We and others (aacrjournals.org/clincancerr…) believe yes: Membranous NECTIN4 expression is correlated to EV response. Further, app. 40% of oUC metastatic samples are lacking membranous NECTIN4 aacrjournals.org/clincancerr…

Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma - @PTarantinoMD @niklas_kluemper #BreastCancer #DanaFarberCancerInstitute #GU24 #HER2 #ExperimentalOncology #LungCancer oncodaily.com/32899.html

Great overview on UC pathology @Markuseckstein3 🔥 important to keep these pathways of UC carcinogenesis in mind for ADC targets as well, as NECTIN4 is overexpressed in luminal tumors as nicely demonstrated by @jonchou05 pubmed.ncbi.nlm.nih.gov/3410… in @CCR_AACR @urotoday @OncoAlert

Our latest paper ist out in @Histo_Journal ! We comprehensively studied the membranous protein expression of the two important #ADC targets TROP2 and NECTIN4 (surfaceome 🏄‍♂️). it is the first paper on protein expression in a large cohort of over 200 muscle-invasive and metastic carcinomas of the urinary bladder. 😊 ➡️read below! @OncoAlert @Uroweb @onkowissen @ASCO @JAMA_current @JAMANetwork @urotoday @niklas_kluemper @IEO_HolzelLab @HolzelMichael onlinelibrary.wiley.com/doi/…

Awesome showing by @UCSFCancer at #BCANTT23 Thank you to @SimaPorten and many of our colleagues @UCSFHospitals including also @friedt02 @Tanjin097 @jonchou05 @xiaolin_zhu @HemoncUcsf @ckcding and our NPs Iva Colon and Krisztina Emodi @BladderCancerUS

Team UCSF at the 2023 BCAN Think Tank! Blessed to have such amazing colleagues and friends @CChuMD @koshkin85 @ckcding @SamWashUro @HeikoYangMDPhD #BCANTT23